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Salvaging prosthetic dialysis fistulas with stents:
Forearm versus upper arm grafts
Stephen Kolakowski, Jr, MD, Matthew J. Dougherty, MD, and Keith D. Calligaro, MD, Philadelphia, Pa
Objective: We compared results of angioplasty with those of concomitant stent placement to treat thrombosed forearm
hemodialysis grafts with results for upper arm grafts.
Material and Methods: Between October 1998 and July 2002, stents were deployed in 61 patients undergoing balloon
angioplasty because of venous anastomotic stenosis causing graft thrombosis. Stents were used only in cases of inadequate
angioplasty results. Twenty-three forearm grafts and 38 upper arm grafts were treated. All procedures were performed in
an endovascular operating suite, with fistulography. Primary and secondary patency rates were analyzed and compared for
graft location with the life table method.
Results: Grafts had undergone a mean of 1.56 previous revisions because of thrombosis (forearm: 1.52, upper arm: 1.58;
PNS). Excluding early thrombosis, a single graft infection was the only procedural complication. Cumulative primary
patency rate at 3, 6, and 12 months (from stent placement) was 36.4%, 15.6%, and 0%, respectively, for forearm grafts,
which was inferior to the 59.5%, 34.0%, and 17.0% primary patency rate observed for upper arm grafts (P  .0307)
Secondary patency rate was 40.9%, 40.9%, and 30.7%, respectively, for forearm grafts, and 64.9%, 42.3%, and 19.7% for
upper arm grafts (P  NS).
Conclusion: Stent deployment can salvage thrombosed dialysis grafts. However, sustained patency occurs infrequently,
with better results for upper arm grafts than for forearm grafts. Inasmuch as surgical revision of forearm grafts is usually
straightforward, stenting should be reserved for use in high axillary grafts and other sites where surgical repair is difficult.
(J Vasc Surg 2003;38:719-23.)
An arteriovenous fistula is the ideal vascular access.
Despite efforts in recent years to maximize access, pros-
thetic bridge grafts are still necessary in about half of
patients, despite inferior patency results.1 The major cause
of graft failure is thrombosis, most frequently secondary to
stenosis at the venous anastomosis, usually secondary to
myointimal hyperplasia. Achieving sustained patency of
these grafts requires frequent salvage procedures.
Endovascular techniques are increasingly used to treat
thrombosed dialysis grafts. Two prospective randomized
studies and a recent meta-analysis of the published experi-
ence have suggested superior patency with surgical revision
compared with endovascular treatment.2-4 However, most
of these series included few patients with intraluminal
stents, which may enhance patency results.5 Because we
have found that suboptimal technical results are common
with angioplasty alone in these fibrotic lesions, we have
used stenting more frequently in the last few years. Optimal
indications for stenting are not well-defined. The objective
of this study was to review our results with stents placed
selectively to treat venous outflow lesions associated with
access graft thrombosis and to compare results of angio-
plasty with concomitant stent placement for forearm versus
upper arm grafts.
METHODS
We identified patients who underwent venous stent
placement at dialysis graft thrombectomy or thrombolysis
between October 1998 and July 2002 at Pennsylvania
Hospital. Grafts were classified as upper arm for grafts with
venous anastomosis proximal to the elbow crease, and as
forearm for venous anastomosis at or below the antecubital
level.
All procedures were performed in an endovascular op-
erating room suite with intraoperative fistulography. Graft
declotting was performed with Fogarty catheter surgical
thrombectomy, mechanical thrombectomy with the An-
giojet Rheolytic Thrombectomy System (Possis Medical,
Minneapolis, Minn), or thrombolysis with pulse-spray
urokinase (Abbott Laboratories, Abbott Park, Ill). In all
patients the indication for stent deployment was inadequate
angioplasty results (30% residual stenosis), usually on the
basis of elastic recoil. We find elastic recoil to be a frequent
issue in percutaneous treatment of venous lesions, probably
because of relatively low intraluminal hydrostatic pressure
and the fibrous nature of the lesions being treated, occur-
ring in approximately 50% of such lesions treated with
angioplasty alone.
Patient demographics, clinical factors, and outcome
were recorded from office and hospital charts. Variables
analyzed included the number and method of previous
interventions on the graft, stent characteristics, procedural
complications, and patency. Primary patency was defined as
the period from stent deployment until any further inter-
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vention or graft abandonment. Secondary patency was
defined as the time from stent placement to graft abandon-
ment, regardless of number and type of interventions. All
grafts were immediately usable for dialysis access after the
procedure, and no patent grafts were unusable for dialysis
during follow-up.
Data were analyzed in accordance with the suggested
standards on reporting of endovascular procedures.6,7 Pri-
mary and secondary patency rates were calculated with the
life table method and were compared with the log-rank
test. P  .05 was considered significant.
RESULTS
Sixty-one patients (44 women, 17 men; mean age, 58
years [range, 27-81 years]) underwent balloon angioplasty
with adjunctive stent placement to treat venous anasto-
motic stenosis leading to prosthetic hemodialysis graft
thrombosis. Thirty-eighty upper arm grafts and 23 forearm
grafts were treated. Preoperative demographic data and risk
factors are illustrated by group in the Table. Approximately
three fourths of the patients were African American, and
three fourths were women. Most patients had hypertension
or diabetes. There were no significant differences in age,
gender, ethnicity, presence of hypertension, and presence
of diabetes mellitus between forearm graft and upper arm
graft groups.
During the study, access procedures performed in-
cluded 176 autogenous fistulas, 302 bridge grafts, 379
surgical graft revisions (302 with thrombectomy), 183
graft thrombectomies, and 146 venous angioplasties. Thus
patients undergoing stenting represented a small subset of
the access population.
In the forearm group, arterial inflow was from the
brachial artery in all patients; venous outflow was to the
basilic vein in 13 patients and to a brachial vein in 10
patients. In the upper arm group, inflow was from the
axillary artery in 29 patients and the above-elbow brachial
artery in 9 patients; outflow was to the brachial vein (prox-
imal to the basilica vein) in 9 patients, the axillary vein
within the arm in 20 patients, and the infraclavicular axillary
vein in 9 patients.
Only nine grafts (three forearm, six upper arm) had
undergone no previous interventions. Mean number of
previous interventions in the same graft was 1.56 (upper
arm: 1.57, forearm: 1.52; P  NS). Two patients under-
went thrombolysis, and 11 patients underwent mechanical
thrombectomy. Most of the group (48 patients, 78.7%)
underwent surgical catheter thrombectomy, and therefore
subgroup analysis was not possible.
All stenotic lesions treated in this cohort were located at
the venous anastomosis or within the main outflow vein.
Stents used included the Wallstent (Boston Scientific,
Natick, Mass) in 57 patients, Palmaz stent (Johnson &
Johnson, New Brunswick, NJ) in 3 patients; and Symphony
stent (Boston Scientific) in 1 patient. Stent size varied from
7 mm  2 cm to 14 mm  4 cm (Fig 1). Stent placement
across the elbow crease and at the thoracic outlet was not
used, because of concern about kinking.
Early graft thrombosis (defined as graft occlusion
within 1 week of the procedure) and graft infection were
the only complications observed. Five early occlusions oc-
curred, all in the forearm graft group. Early failure was thus
significantly more likely in forearm grafts compared with
upper arm grafts (P  .0027). One graft infection, in an
upper arm graft, developed at 35 days postoperatively.
In the upper arm graft group, all 38 stents attempted
were deployed successfully. Follow-up averaged 216 days
(range, 29-820 days). Cumulative primary patency rate at
3, 6, and 12 months after stent placement was 59.5%,
34.0%, and 17.0%, respectively (Fig 2, A), and secondary
patency rate was 64.9%, 42.3%, and 19.7%, respectively (Fig
2, B). Two patients were lost to follow-up.
In the forearm graft group, all 23 stents attempted were
deployed successfully. Mean follow-up was 129 days
(range, 1-664 days). Cumulative primary patency rate at 3,
6, and 12 months was 36.4%, 15.6%, and 0%, respectively
(Fig 2, A), and secondary patency rate was 40.9%, 40.9%,
and 30.7%, respectively (Fig 2, B). One patient was lost to
follow-up at 350 days after successful kidney transplanta-
tion.
Mean number of interventions after stent placement
during follow-up was .52 for upper arm grafts and .43 for
Table I. Demographic data and comorbid conditions
Characteristic
Forearm group Upper arm group Total
Pn % n % n %
No. of patients 23 38 61
Mean age 57 59 58 .85
Range 27-85 38-80 27-85
Gender
Male 7 41 10 59 17 72 .467
Female 16 36 28 64 44 28 .070
Ethnicity
African American 16 30 31 70 47 77 .028
White 6 50 6 50 12 20 1.00
Other 1 50 1 50 2 3 1.00
Hypertension 21 91 35 92 56 92 .061
Diabetes mellitus 12 52 25 66 37 61 .032
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forearm grafts (P  NS). At log-rank comparison of graft
survival curves, primary patency for upper arm grafts was
significantly superior to results for forearm grafts (P 
.0307). However, there was no statistically significant dif-
ference in secondary patency between groups.
DISCUSSION
The 2000 United States Renal Data System (USRDS)
reported that Medicare expenses for vascular access in
patients receiving hemodialysis account for 14% to 17% of
total spending for end-stage renal disease. This represents
an annual cost of about $8000 per patient. USRDS indi-
cates that 25% of Medicare spending for end-stage renal
disease, approximately 3 billion dollars per year, is spent on
vascular access alone.1 More than 20% of all hemodialysis-
related admissions in the United States are access-related.8
Maintenance of access remains a critical challenge in the
increasingly older and sicker population receiving hemodi-
alysis. In a prospective randomized study of endovascular
versus open treatment of thrombosed dialysis grafts, we
observed a trend toward superior patency with surgical
intervention that did not reach statistical significance. In a
recent meta-analysis of the available literature, including
prospective trials of interventional and surgical graft sal-
vage, it was concluded that surgical thrombectomy remains
the standard for treatment of thrombosed prosthetic vas-
cular access grafts, with superior patency and lower cost
compared with catheter-based techniques.4
It has been our experience in performing balloon an-
gioplasty of venous anastomotic lesions, which in our cen-
ter are responsible for about 80% of graft occlusions, that
suboptimal angiographic results are common.2 The fibrous
nature of the lesion and relatively low luminal pressure at
the venous location combine to make elastic recoil a signif-
icant problem. Inferior results with angioplasty compared
with surgery may in part reflect these suboptimal technical
results, and the available published controlled studies in-
cluded few patients in whom stents were placed because of
this indication.
Adjunctive stenting with angioplasty to restore patency
of occluded hemodialysis grafts was first reported in 1993.9
Several reports have concluded that stent deployment is an
accepted therapeutic manuever to salvage thrombosed di-
alysis grafts, but sustained patency, as with other interven-
tions, is infrequent.10,11 Overall primary patency rate at 1
year in this cohort was low, at 17%. This result is similar to
the 3% to 36% 1-year primary patency rate others have
observed.2 The question as to whether stenting signifi-
cantly improves results of endovascular treatment has not
been answered. Likewise, subgroups in which results may
be better or worse have not been defined.
In several small series, including our own, primary graft
patency after hemodialysis graft thrombectomy, angio-
plasty, and stent placement has been poor, in the range of
12% to 15% at 1 year, not obviously superior to angioplasty
results alone.5,12 However, these patients tend to represent
a subset at high risk, particularly because stents are placed
when angioplasty alone yields inadequate technical results.
Although most studies have found superior patency for
surgery compared with balloon angioplasty in occluded
grafts,3,4 in a case-control comparison of stenting and
surgical patch angioplasty we found no statistically signifi-
cant difference between groups.5 Although the ideal study
to evaluate the adjunctive benefit of stents would compare
angioplasty alone with selected stents, it would be difficult
to accept poor technical results with angioplasty alone in a
prospective study.
In addition to cost and potential need for secondary
procedures, another concern is that subsequent surgery
may be more difficult with the stent in the outflow vein. For
this reason, we limit the length of the stent to cover only the
lesion proper in most cases, and extend the stent into the
graft when necessary.
The results of this study suggest that stenting the
venous anastomosis for forearm grafts yields results inferior
to those at more proximal locations. Although we did not
stratify by vein size in this analysis, most upper arm veins are
larger than forearm veins, and vein diameter may have been
a factor in the difference in primary patency rate. Superior
results with larger veins and greater venous flow are also
observed with stenting of central venous lesions. Haage et
al13 reported a 56% primary patency rate at 12 months for
such lesions. This may reflect better performance in higher
flow situations, as observed with stents in the arterial tree.
Fig 1. A, Axillary venous anastomosis after angioplasty alone. B,
Axillary venous anastomosis after stent deployment.
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It is also possible that, despite efforts to avoid stenting
across the elbow crease, kinking of stents may have occurred in
some patients in the forearm group. We observed at least two
patients with evidence of stent compression at this location.
Given the rapid evolution of stent and thrombectomy
technologies, it is difficult to obtain good prospective,
comparative data on competing techniques of intervention.
In our center, and on the basis of our experience, we
selectively use both open and endovascular techniques.
Access to outflow veins is readily achievable with relatively
simple surgical techniques for forearm grafts. In general,
surgery is more effective than endovascular intervention for
graft occlusion. Given the inferior stent patency results in
forearm grafts in our series, along with these facts, we prefer
surgical thrombectomy and revision as primary treatment
for thrombosed forearm dialysis grafts. For upper arm
grafts, results with stents may be competitive with surgical
results, and endovascular treatment has a role. We particu-
larly prefer this approach in obese patients with high axillary
or infraclavicular venous anastomoses, because the risk for
surgical morbidity (eg, infection, nerve injury, anesthesia-
related complications) may be higher in this setting.
Whether newer methods such as stent grafts or drug-
eluting stents will produce better patency, justifying an
Fig 2. A, Primary patency rate, upper arm grafts (diamonds) versus forearm grafts (squares). B, Secondary patency.
Standard error of mean exceeds 10% beyond 23 months for A and beyond 17 months for B.
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increasing endovascular role for dialysis graft salvage, re-
mains to be seen.
Inasmuch as the durability of both endovascular and
surgical revision of thrombosed dialysis grafts is poor in
most patients, concomitant autogenous fistula construc-
tion in the contralateral arm should be considered when
declotting a graft. Revision procedures such as angioplasty
or stenting should be considered a bridge to establishment
of more durable autogenous access.
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